Illumina Accelerator

Dama Health offers insights into unique predispositions, efficacy, and side effect profiles. Dama Health uses genetic testing and an automated matching system to match individuals to the best options for their unique needs.

Nusantics is a precision molecular diagnostics startup from Indonesia; we develop PCR and Next Generation Sequencing-based solutions to improve healthcare outcomes in both human and animal applications. We offer 3 types of products; single pathogen molecular diagnostics, syndromic molecular diagnostics, and microbiome diagnostics (NGS)

Terrapeutics Pharma develops a drug discovery platform that is based on a groundbreaking technology.

Rethink Bio is a synthetic biology company from India, is focused on harnessing the potential of microalgae to develop sustainable food solutions to benefit the planet and people.

Biomolecules are the next bits of the 21st century. So we're developing the first wet operating system for storing, accessing, and computing biomolecules at scale to make them widely accessible and useful. We're enabling the storage and access to the whole data universe—digital and biological—forever so that we don't have to delete or dispose of anything ever again.

NonExomics integrates genomics, transcriptomic, and proteomics data by utilizing proprietary machine learning approaches to predict structures of nonexomic proteins and identifies disease-specific nonexomic targets, allowing clients to find cures for rare diseases.

Purpose Health, Inc. a mental wellness company from Northern Virginia, supports consumers on their mental wellness journey with data-driven insights into the physiological impact of stress on the microbiome and body.

B4X, INC., a therapeutics and diagnostics company from Atlanta, Georgia, is utilizing multi-omic big data anchored in genomics to deliver life-saving therapeutics and precision diagnostics to individuals suffering from debilitating diseases of the brain.

4SR Biosciences Inc., a diagnostics and therapeutics company from University of Chicago, is using proprietary technology to explore new tRNA-based modalities for disease biomarkers and cancer therapeutics.

CRISP-HR a therapeutics company has developed a proprietary, next-generation CRISPR platform to create novel therapeutics for rare diseases.

Genegoggle is a precision medicine biotech company with the goal of discovering novel therapeutics and intelligent systems to improve human health by leveraging multi-dimensional genomic and epigenetic elements.

Yali Biosciences is a food tech company that uses synthetic biology and genomics tools to make climate-smart, sustainable foods.

NewStem is a Jerusalem-based biotech with a novel precision-medicine technology that can increase chemotherapy's effectiveness. NewStem is a spinoff of Yissum, The Technology Transfer Company of The Hebrew University. NewStem's technology can predict patients' resistance to chemotherapy allowing for better, targeted cancer treatments and the potential to reduce resistance to chemotherapy.

ImYoo is building a patient-centric biodiscovery ecosystem by combining high-resolution assays and patient convenience.

Solena is a biotechnology company dedicated to the study of the microbiome of agricultural soils, with the aim of increasing the profitability of farmers by tailored biological inputs

Bixbio is a biotechnology company working to unlock the potential of diverse genetic data in Africa to transform the field of precision medicine.

EpiCombi.AI is a genomics signature-driven therapeutics spinout from Oxford University, is overcoming epigenetic barriers in cancer complexity through the creation of AI-derived, network-acting multi-targeted drugs.

Broken String Biosciences is developing a platform of novel sequencing tools to assess genome stability and to unlock the next generation of innovative medicines, including cell and gene therapies.

Biotax is a leading provider of cutting-edge technologies and services, offering biological and genomic informatics solutions for pharma companies, hospitals, and medical centers. Founded by a group of leading researchers who's mission is to help patients by creating new diagnostics and treatments protocols.

Rubik Therapeutics is a platform therapeutics company developing next gen cell therapies for solid tumors. Rubik's computational engine and genome scale discovery tools have identified a set of unique genetic modulators that endow immune cells (T and NK) with potent and selective anti-tumor activity.

Flightpath Biosciences is a biotechnology company that develops medications to treat rare infectious diseases. The company is bridging scientific unknowns by interrogating disparate fields of biology, taking risks, innovating, and deploying potentially orthogonal approaches to achieve desired outcomes. It is working with leading scientists, therapeutics, and diagnostics experts across multiple scientific disciplines within several esteemed academic institutions and government agencies to create novel, targeted solutions. The company was founded in 2019 and is based in Berkeley, California.

MultiplAI leverages genomics and AI to provide universal remote screening for cardiovascular diseases among other complex diseases. We use a liquid biopsy of whole blood based on RNA sequencing and deep learning looking at all biomarkers in the blood, thus creating a superb biomarker to detect diseases earlier. Our test can be used in continuous testing both for preventative screening and post-treatment monitoring. Given that it requires only a simple blood sample, it can be administered remotely, anywhere, and costs a fraction of existing diagnostic methods.

Oshun Medical is an innovative diagnostic and digital health company exclusively committed to advancing the health of women and championing awareness of their healthcare issues.

Powered by genomics, skin microbiome science, and machine learning, Parallel is an end-to-end next-generation skin health company providing derm telehealth, cutting-edge skin microbiome diagnostics, precision microbiome skincare, and personalized Rx

Grail develops a pan-cancer screening test designed to detect cancers at an early stage. Its pan-cancer screening test measures circulating nucleic acids in blood using high-intensity sequencing, population-scale clinical trials, enabling doctors to develop blood tests for early-stage cancer detection. The company was founded in 2016 by Alex Aravanis and Jeff Huber in Menlo Park, California.

Bluebee is a leading provider of high performance genomics solutions, enabling research and clinical labs to substantially reduce cost and time-to-diagnose. Bluebee provides a unique cloud-based accelerated genomics platform to enable fast, efficient and affordable processing of large volumes of genomics data. Genetic analyses are currently undergoing extreme changes as a result of revolutionary developments in next generation DNA sequencing technology. While personalized treatment comes with great promises, routine clinical implementation of whole genome based diagnostics is still faced with major technological and biological challenges: the ever-growing amounts of data generated, the inherent need for faster data processing and deep analytics, and the increasing necessity of flexibility and reliability resulting from the vastness of the application spectrum.

Ginkgo Bioworks is a biotechnology firm. It is a developer of biological engineering products and custom microbes across multiple markets. It designs, engineer, develops, tests, and licenses organisms. It discovers molecules in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. It also provides probiotic bacteria to protect the body from dangerous infections, and it generates libraries of molecules. It serves cultured ingredients, carbon mitigation, probiotics, and natural product discovery markets.

Grail develops a pan-cancer screening test designed to detect cancers at an early stage. Its pan-cancer screening test measures circulating nucleic acids in blood using high-intensity sequencing, population-scale clinical trials, enabling doctors to develop blood tests for early-stage cancer detection. The company was founded in 2016 by Alex Aravanis and Jeff Huber in Menlo Park, California.

Helixis, Inc. is a company that develops low-cost molecular diagnostic products.

Biome Makers is a biotech company born in Silicon Valley specialized in the identification and understanding of the microbiome. They use DNA Sequencing technologies and proprietary Intelligent Computing systems to ease detailed information and recommendations that allow customers improve their agricultural production and the quality of their products.

Trace Genomics is specializing in soil health and microbiome analysis. They focus on providing advanced genetic insights into soil, helping farmers optimize their agricultural practices for better crop yield and sustainability. Trace Genomics utilizes next-generation sequencing technologies to analyze the microbial composition of soil, offering information about the diversity and abundance of microorganisms present. This data can be valuable for farmers in making informed decisions about soil management, crop selection, and the application of fertilizers and other inputs. The company aims to empower farmers with actionable information to enhance soil health, increase crop productivity, and contribute to sustainable agriculture practices.

Conexio-Genomics is a privately operating life sciences company located in Fremantle, Western Australia.

Grail develops a pan-cancer screening test designed to detect cancers at an early stage. Its pan-cancer screening test measures circulating nucleic acids in blood using high-intensity sequencing, population-scale clinical trials, enabling doctors to develop blood tests for early-stage cancer detection. The company was founded in 2016 by Alex Aravanis and Jeff Huber in Menlo Park, California.

NextGen Jane is a data-driven women's health company offering a woman insight into her reproductive health through a smart tampon system to track biological changes predictive of disease. The company's smart tampon platform allows users to conveniently mail-in cells from the reproductive tract that are shed during menstruation. It focuses on developing tests based on a patented tampon collection technology.

Their founding team possesses a unique combination of expertise in synthetic biology, environmental genomics, and bioinformatics. They founded MetaMixis to enable the emergence of the bioeconomy by revolutionizing enzyme and pathway discovery. Along the way, they've brought in a world-class Board who they enjoy learning from every day.

Vitagene leverages big data and machine learning to provide personalized, actionable diet, fitness, and supplement recommendations to its members.

GenoLogics provides discovery and biomedical solutions that can be implemented across multiple labs and support translational medicine and systems biology initiatives. Their vision is to catalyze life sciences research with a collaborative data management software platform, advancing the early detection, prevention, and treatment of disease.

A genomics company, developing noninvasive urine-based nucleic acid sequencing diagnostics for the detection and monitoring of cancer.

Biome Makers is a biotech company born in Silicon Valley specialized in the identification and understanding of the microbiome. They use DNA Sequencing technologies and proprietary Intelligent Computing systems to ease detailed information and recommendations that allow customers improve their agricultural production and the quality of their products.

Xcell Biosciences is a San Francisco-based life science start-up company that is developing novel and disruptive systems for cell therapy development and production. Their proprietary technology enables fine control of primary cell phenotype and function, enabling an entirely new capability for optimizing efficacy and persistence of immune cell therapies.

Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad range of severe genetic disorders. The company's therapy pipeline addresses devastating genetic and acquired disorders spanning multiple disease pathways including neurocircuitry, metabolic disorders, neurodegeneration and cardiovascular disease, enabling medical practitioners to treat patients and improve their lives.

EpiBiome is a venture-backed precision microbiome engineering company tackling the challenge of antibiotic resistance by developing alternatives to small-molecule antibiotics for use in healthcare, veterinary and agriculture industries. Antibiotic-resistant bacteria surpass nuclear warfare, climate change, and terrorism as the biggest challenge facing humanity today. The pipeline of new antibiotics has slowed to a trickle, while the emergence of multi-drug resistant bacteria is on an unprecedented trajectory. These bacteria threaten to reverse more than 100 years of medical progress by making all but the most necessary surgical procedures too risky due to the threat of post-operative infection.

Advanced Liquid Logic, Inc is a multidisciplinary team of scientists, engineers and product developers committed to providing unique workflow solutions to unmet challenges in laboratories and clinics. Dr. Michael Pollack and Dr. Vamsee Pamula founded the company in 2004 and remain engaged full time with the company as co-CTO’s. Vamsee and Michael developed the core technology while completing their doctorates and post doctoral research at Duke University’s Pratt School of Engineering. The company is led by an experienced CEO, Richard West, who joined ALL in 2005. Rich has 15 year’s experience as a CEO and a cumulative 30 years in business and product development management.

Moleculo is a biotech company that focuses on developing technologies for generating long reads for genome analysis tools. The company has developed a novel DNA sequencing method that provides long and accurate reads, thereby improving the efficiency and accuracy of many existing DNA sequencing applications, enabling clients to get a range of new applications.

Verinata is driven by a sole, extraordinary purpose – maternal and fetal health. Our initial focus is to develop and offer non-invasive tests for early identification of fetal chromosomal abnormalities using our proprietary technologies. We aim to reduce the anxiety associated with today's multi-step process, the unacceptable false-positive rates, the non-specific and sometimes confusing results of current prenatal screening methods, as well as the risk of current invasive procedures. In support of national guidelines recommending first trimester aneuploidy risk assessment, we believe women who desire such an assessment should be offered a single blood draw test with a definitive result. Verinata is conducting a prospective, blinded pivotal study to clinically validate the sensitivity and specificity of its first prenatal test on a large scale with results of the study expected in 2011.

Epicentre, is a manufacturer and seller of high-quality molecular biology products for life science research, clinical research, molecular diagnostics and biopharmaceutical manufacturing. Products are available for RNA amplification and gene expression analysis, transposon-based genetic analysis, DNA and RNA purification, DNA sequencing, PCR and RT-PCR amplification, DNA and RNA modifying enzymes, genomic cloning, in vitro transcription, and protein research and purification. In addition to our broad molecular biology product line, Epicentre also offers custom protein manufacturing.

Affomix has proprietary technology for rapid, automated, high-throughput selection of human monoclonal antibodies (mAbs). Their mission is to commercialize proprietary mAbs, mAb microarrays and mAb libraries for research, drug discovery, diagnostic and therapeutic applications, with a particular focus on the use of their mAbs for sensitive and accurate measurement of very large numbers of proteins in biological samples.

Helixis, Inc. is a company that develops low-cost molecular diagnostic products.

Oxford Nanopore Technologies is a biotechnology company that develops and commercializes nanopore sequencing technology. Their novel, electronics-based DNA/RNA sequencing technology is being used in more than 80 countries, for a range of biological research applications. These include large scale human genomics, cancer research, microbiology, plant science, and environmental research. Nanopore sequencing is also being explored beyond research, where it has the potential to provide rapid, meaningful information in the fields of healthcare, agriculture, food and water surveillance, and education. Oxford Nanopore’s proprietary technology is fully scalable for any requirement. Small formats such as Flongle address the need for on-demand, rapid, smaller tests or experiments, and can be used in labs or in the field. The pocket-sized MinION is a powerful and portable sequencing device that can deliver high volumes of long-read sequence data. The benchtop GridION X5 can run up to five MinION Flow Cells at a time, on-demand, for larger genomics projects. The recently launched PromethION is the largest format for nanopore sequencing, designed to offer on-demand use of up to 48 Flow Cells – each of which can offer more than 100Gb of sequencing data. Focusing on ease of use, nanopore sequencing offers easy and rapid preparation, including a ten-minute library preparation kit and the automated, programmable VolTRAX. Supported by a broad patent portfolio, the Oxford Nanopore pipeline includes multiple generations of nanopore-based sensing technologies, including those based on both biological and solid-state nanopores.

Solexa engages in developing and commercializing genetic analysis technologies primarily in the United States and the United Kingdom. The company is developing and preparing Solexa Genome Analysis System, which performs DNA sequencing based on its proprietary reversible terminator Sequencing-by-Synthesis, chemistry, and Clonal Single Molecule Array technology. Its platform is designed to support a range of analyses, including whole genome resequencing, gene expression analysis, and small RNA analysis.